US equities |
INTC $112.50 ▲+0.00% MU $1,045.56 ▲+0.00% SNDK $1,660.46 ▲+0.00% NVDA $239.24 ▲+0.00% SPCX $171.92 ▲+0.00% MRVL $287.01 ▲+0.00% AMD $649.42 ▲+0.00% MSTR $164.55 ▲+0.00%
FinancialContent

Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

12.07 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amarin Corporation plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
Data Supports Approximately 30% Relative Risk Reduction Among Highly Adherent Patients and Provides Evidence Consistent with a Potential Legacy Effect in Secondary Prevention Patients After Treatment... 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin (AMRN) Q2 2026 Earnings Call Transcript ↗
Amarin narrows losses while expanding global market reach across 22 countries. 
Via The Motley Fool
Topics Earnings
Amarin Posts Surprise Q2 Profit on Cost Discipline, Shares Rise Pre-Market (NASDAQ:AMRN) ↗
Via Chartmill
Amarin (NASDAQ:AMRN) Surprises with Revenue Beat but EPS Falls Short Amid Restructuring Costs ↗
Via Chartmill
News headline image
Amarin Q2 Earnings Call Highlights ↗
Amarin (NASDAQ:AMRN) said its second-quarter results reflected progress in its dual commercial strategy, which combines a company-managed U.S. business with partnered commercialization internationally.... 
Via MarketBeat
Topics Earnings
News headline image
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides 
From Amarin Corporation plc
Via GlobeNewswire
Amarin Corp (NASDAQ:AMRN) Narrows Losses and Beats Adjusted EPS in Q4 2025 ↗
Via Chartmill
News headline image
New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin (AMRN) Q1 2026 Earnings Transcript ↗
Amarin (AMRN) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Amarin Reports 2026 First Quarter Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin (AMRN) Q2 2025 Earnings Transcript ↗
Amarin (AMRN) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Amarin (AMRN) Q3 2025 Earnings Transcript ↗
Amarin (AMRN) Q3 2025 Earnings Transcript 
Via The Motley Fool
Topics World Trade
News headline image
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks ↗
Amarin is milking a cash cow, but it looks like that cow is slowly being bled to death. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now ↗
One is speculative, the other is a reliable blue chip company. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin (AMRN) Q4 2025 Earnings Call Transcript ↗
Amarin (AMRN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
U.S. IPE Market Leadership Sustained; $70M Restructuring OPEX Savings on Pace for Mid-2026; Completed Transition to Fully Partnered Model Across All International Markets 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
From Amarin Corporation plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >